Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer

Oncology

Volumn 65, Issue 3, 2003, Pages 211-217

  Schüll, Birgit ^a   Kornek, Gabriela V ^a   Schmid, Katharina ^a   Raderer, Markus ^a   Hejna, Michael ^a   Lenauer, Alfred ^b   Depisch, Dieter ^b   Lang, Fritz ^c   Scheithauer, Werner ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Hospital of Neunkirchen   (Austria)

Author keywords

Advanced gastric cancer; Cisplatin; Docetaxel; Erythropoietin; Granulocyte colony stimulating factor; Palliative chemotherapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CISPLATIN; DOCETAXEL; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HEMOPOIETIC GROWTH FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; ESOPHAGUS CARCINOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; MALE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SKIN TOXICITY; STOMACH CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 18744418006     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074473     Document Type: Article

References (38)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
2. Alexander HR, Kelson DP, Tepper JE: Cancer of the stomach; in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology, ed 4. Philadelphia, Lippincott, 1993, pp 818-848.
3. Glimelius B, Ekström K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive case in advanced gastric cancer. Ann Oncol 1997;8:163-168.
4. Pyrhonen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
5. Scheithauer W, Kornek GV, Zeh B, et al: Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer. A randomized trial (abstract). Second Int Conf Biol Prev Treat GI, Malign, Köln, 1995, p 68.
6. Wils J: The treatment of advanced gastric cancer. Semin Oncol 1996;23:397-406.
7. Fuchs CS: Chemotherapy for advanced gastric cancer. Where do we stand? J Clin Oncol 1997;15:3299-3000.
8. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997;15:261-267.
9. Ross P, Nicolson M, Cunningham D, et al: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
10. Morant R: Neoadjuvant and adjuvant chemotherapy of locally advanced stomach cancer. Onkologie 2001;24:116-121.
11. Findlay M, Cunningham D, Norman A, et al: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994;5:609-616.
12. Tanka M, Obata T, Sasaki T: Evaluation of antitumor effects of docetaxel (Taxotere) on human gastric cancers in vitro and in vivo. Eur J Cancer 1996;32A:226-230.
13. Einzig AI, Neuberg D, Remick SC, et al: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996;13:87-93.
14. Mai M, Sakata Y, Kanamaru M, et al: A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: A cooperative study group trial (group B). Gan To Kagaku Ryoho 1999;26:487-496.
15. Mavroudis D, Kourousis C, Androulakis N, et al: Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): A phase II trial. Am J Oncol 2000;23:341-344.
16. Sulkes A, Smyth J, Sessa C, et al: Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994;70:380-383.
17. Furue H, Taguchi T: A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer. Ann On-col 1998;9 (suppl 4): 233P.
18. Wilke H, Vanhoefer U, Harstrick A, et al: Phase II study of docetaxel as salvage chemotherapy in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 1998;17:305.
19. Roth AD, Maibach R, Martinelli G, et al: Do-cetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO). Ann Oncol 2000;11:301-306.
20. Ridwelski K, Gebauer T, Fahlke J, et al: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 2001;12:47-51.
21. Kettner E, Ridwelski K, Keilholz U, et al: Docetaxel and cisplatin combination chemotherapy for advanced gastric cancer: Results of two phase II studies. Proc ASCO 2001;20:165a.
22. Pierelli L, Perillo A, Greggi S, et al: Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, docetaxel, and cisplatin combination chemotherapy: Results of a randomized comparison. J Clin Oncol 1999;17:1288-1295.
23. Littlewood TJ: The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;2(suppl 8):49-53.
24. Gehan EA: The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;2: 346-353.
25. Anderson JR, Bernstein L, Pike MCI: Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics 1982;38:407-416.
26. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:458-481.
27. Bokemeyer C, Hartmann JT, Lampe CS, et al: Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 1997;24(6 suppl 19):S19-96-S19-100.
28. Murad AM, Petroianu A, Guimaraes RC, et al: Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: A novel, safe, and effective regimen. Am J Clin Oncol 1999;22:580-586.
29. Kollmannsberger C, Quietzsch D, Haag C, et al: A phase II study of paclitaxel, weekly, 24-hour continuous infusion fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000;83:458-462.
30. Boku N, Ohtsu A, Shimada Y, et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-323.
31. Kelsen D, Atiq O, Saltz L, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 1992;10:541-548.
32. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouacil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18:2648-2657.
33. Cascinu S, Labianca R, Alessandroni P, et al: Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione, and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997;15:3313-3319.
34. Kock HJ, Pietsch M, Krause U, et al: Implantable vascular access systems: Experience in 1,500 patients with totally implanted central venous port system. World J Surg 1998;22:12-16.
35. Lemmers NW, Gels ME, Slijfer DT, et al: Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. J Clin Oncol 1996;14:2916-2922.
36. Spielmann M, Llombart A, Zelek L, et al: Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol 1999;10: 1457-1460.
37. Kim YH, Kim JS, Choi YH, et al: Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer. Int J Clin Oncol 2002;7:114-119.
38. Glisson BS, Murphy BA, Frenette G, et al: Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 2002;20:1593-1599.